Our data confirm long-term CDE treatment as an experimental regime that recapitulates the hallmarks of chronic pancreatitis and will initiate further studies evaluating TWEAK/Fn14 signalling as a novel therapeutic target in pancreatic disease. The gene discussed is TNFRSF12A; the disease is chronic pancreatitis.